Top 100 Contractors in NAICS 3254: Pharmaceutical and Medicine Manufacturing, FY2023

Parent companies by net contract obligations Oct 1, 2022 – Sep 30, 2023 Code page on GovTribe

The top 10 won 88% of FY2023 NAICS 3254 contract dollars

Ranking facts

Contract obligations
$18,173,452,861 Net of deobligations, by contracts coded NAICS 3254 or a code under it
Contractors
625 Parent companies with an obligation
Largest contractor
Mckesson Corporation $10.2 billion, 55.1% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $10,218,021,762
Rank history: #2 in FY2021, #2 in FY2022, #1 in FY2024 and #1 in FY2025; up 1 since FY2022.
2 $1,881,654,997
Rank history: #1 in FY2021, #1 in FY2022, not on the FY2024 list and #71 in FY2025; down 1 since FY2022.
3
Amerisourcebergen Corporation 2 awardees, including Amerisourcebergen Drug Corp
$1,380,710,240
Rank history: not on the FY2021 list, #30 in FY2022, #3 in FY2024 and not on the FY2025 list; up 27 since FY2022.
4 $1,244,720,696
Rank history: #8 in FY2021, #14 in FY2022, #2 in FY2024 and #2 in FY2025; up 10 since FY2022.
5 $357,750,000
Rank history: not on the FY2021 list, #6 in FY2022 and not on the FY2024–FY2025 lists; up 1 since FY2022.
6 $340,654,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
7 $284,689,316
Rank history: #6 in FY2021, #5 in FY2022, not on the FY2024 list and #30 in FY2025; down 2 since FY2022.
8 $242,337,992
Rank history: #10 in FY2021, #18 in FY2022 and not on the FY2024–FY2025 lists; up 10 since FY2022.
9 $237,000,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
10 $179,906,606
Rank history: #15 in FY2021, #10 in FY2022 and not on the FY2024–FY2025 lists; unchanged since FY2022.
11 $137,831,082
Rank history: #16 in FY2021, #17 in FY2022, #22 in FY2024 and #15 in FY2025; up 6 since FY2022.
12 $125,526,228
Rank history: #13 in FY2021, #15 in FY2022, #7 in FY2024 and #5 in FY2025; up 3 since FY2022.
13 $110,361,242
Rank history: #32 in FY2021, #9 in FY2022, #34 in FY2024 and not on the FY2025 list; down 4 since FY2022.
14 $86,400,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
15 $80,550,000
Rank history: #24 in FY2021, #21 in FY2022, #12 in FY2024 and #7 in FY2025; up 6 since FY2022.
16 $73,658,688
Rank history: not on the FY2021 list, #98 in FY2022 and not on the FY2024–FY2025 lists; up 82 since FY2022.
17 $69,881,910
Rank history: #17 in FY2021, #13 in FY2022 and not on the FY2024–FY2025 lists; down 4 since FY2022.
18 $61,236,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
19 $52,236,000
Rank history: not on the FY2021 list, #26 in FY2022 and not on the FY2024–FY2025 lists; up 7 since FY2022.
20 $50,649,404
Rank history: not on the FY2021 list, #19 in FY2022, #11 in FY2024 and #33 in FY2025; down 1 since FY2022.
21 $48,044,093
Rank history: #3 in FY2021, #4 in FY2022 and not on the FY2024–FY2025 lists; down 17 since FY2022.
22 $46,003,286
Rank history: #29 in FY2021, #22 in FY2022, #26 in FY2024 and #27 in FY2025; unchanged since FY2022.
23 $41,553,957
Rank history: #82 in FY2021, #41 in FY2022, #61 in FY2024 and not on the FY2025 list; up 18 since FY2022.
24 $38,992,244
Rank history: #30 in FY2021, #33 in FY2022, #21 in FY2024 and #17 in FY2025; up 9 since FY2022.
25
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$36,142,176
Rank history: #26 in FY2021, #32 in FY2022, #51 in FY2024 and not on the FY2025 list; up 7 since FY2022.
26 $32,379,816
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
27 $31,384,584
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
28 $30,846,731
Rank history: #20 in FY2021, #24 in FY2022, #19 in FY2024 and #23 in FY2025; down 4 since FY2022.
29 $28,728,000
Rank history: #51 in FY2021, not on the FY2022 list and not on the FY2024–FY2025 lists; returned.
30 $28,341,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 407 since FY2022.
31 $26,753,869
Rank history: not on the FY2021 list, #46 in FY2022, #23 in FY2024 and #19 in FY2025; up 15 since FY2022.
32 $26,355,497
Rank history: #31 in FY2021, #39 in FY2022, #35 in FY2024 and not on the FY2025 list; up 7 since FY2022.
33 $23,338,950
Rank history: not on the FY2021 list, #27 in FY2022 and not on the FY2024–FY2025 lists; down 6 since FY2022.
34 $22,199,262
Rank history: not on the FY2021 list, #25 in FY2022, #30 in FY2024 and #16 in FY2025; down 9 since FY2022.
35 $21,705,831
Rank history: #58 in FY2021, #58 in FY2022, #28 in FY2024 and not on the FY2025 list; up 23 since FY2022.
36 $20,830,193
Rank history: #41 in FY2021, #49 in FY2022 and not on the FY2024–FY2025 lists; up 13 since FY2022.
37 $20,557,320
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
38 $16,985,826
Rank history: not on the FY2021 list, #42 in FY2022 and not on the FY2024–FY2025 lists; up 4 since FY2022.
39 $15,636,270
Rank history: #34 in FY2021, #38 in FY2022, #32 in FY2024 and not on the FY2025 list; down 1 since FY2022.
40
Boehringer Ingelheim Corporation 2 awardees, including Boehringer Ingelheim Animal Health France
$14,362,467
Rank history: #37 in FY2021, #43 in FY2022 and not on the FY2024–FY2025 lists; up 3 since FY2022.
41 $13,270,926
Rank history: #38 in FY2021, #56 in FY2022, #43 in FY2024 and not on the FY2025 list; up 15 since FY2022.
42 $13,043,552
Rank history: #14 in FY2021, #40 in FY2022, #75 in FY2024 and not on the FY2025 list; down 2 since FY2022.
43 $12,420,731
Rank history: #53 in FY2021, not on the FY2022 list, #48 in FY2024 and #8 in FY2025; up 59 since FY2022.
44 $12,032,000
Rank history: #47 in FY2021, #31 in FY2022 and not on the FY2024–FY2025 lists; down 13 since FY2022.
45 $11,896,942
Rank history: #56 in FY2021, #54 in FY2022, #50 in FY2024 and #52 in FY2025; up 9 since FY2022.
46 $10,398,471
Rank history: not on the FY2021 list, #53 in FY2022, #44 in FY2024 and not on the FY2025 list; up 7 since FY2022.
47 $10,075,964
Rank history: #22 in FY2021, #37 in FY2022, #29 in FY2024 and not on the FY2025 list; down 10 since FY2022.
48 $9,325,637
Rank history: not on the FY2021 list, #16 in FY2022, not on the FY2024 list and #6 in FY2025; down 32 since FY2022.
49 $8,522,400
Rank history: #65 in FY2021, #66 in FY2022, #59 in FY2024 and #41 in FY2025; up 17 since FY2022.
50 $7,406,739
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
51 $7,271,583
Rank history: #67 in FY2021, #96 in FY2022, #58 in FY2024 and not on the FY2025 list; up 45 since FY2022.
52 $7,224,644
Rank history: #71 in FY2021, #59 in FY2022, #62 in FY2024 and not on the FY2025 list; up 7 since FY2022.
53 $7,190,561
Rank history: #52 in FY2021, #62 in FY2022, #52 in FY2024 and #97 in FY2025; up 9 since FY2022.
54 $6,749,845
Rank history: #55 in FY2021, #11 in FY2022, #49 in FY2024 and not on the FY2025 list; down 43 since FY2022.
55 $6,603,535
Rank history: #42 in FY2021, #47 in FY2022, #41 in FY2024 and #83 in FY2025; down 8 since FY2022.
56 $6,334,667
Rank history: #66 in FY2021, #60 in FY2022, #68 in FY2024 and #40 in FY2025; up 4 since FY2022.
57 $6,310,950
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #25 in FY2025; new.
58 $6,303,001
Rank history: #79 in FY2021, #94 in FY2022, #55 in FY2024 and #45 in FY2025; up 36 since FY2022.
59 $5,888,912
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 67 since FY2022.
60 $5,510,426
Rank history: not on the FY2021 list, #48 in FY2022, #40 in FY2024 and not on the FY2025 list; down 12 since FY2022.
61
Boehringer Ingelheim Animal Health USA Inc
$4,848,030
Rank history: not on the FY2021–FY2022 lists, #46 in FY2024 and #38 in FY2025; new.
62 $4,732,817
Rank history: #39 in FY2021, #20 in FY2022, #88 in FY2024 and not on the FY2025 list; down 42 since FY2022.
63 $4,554,387
Rank history: #9 in FY2021, #7 in FY2022, #14 in FY2024 and #20 in FY2025; down 56 since FY2022.
64
Genabio Diagnostics Inc.
$4,500,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
65 $4,491,708
Rank history: #99 in FY2021, #70 in FY2022, #72 in FY2024 and #64 in FY2025; up 5 since FY2022.
66 $4,387,477
Rank history: #69 in FY2021, #68 in FY2022, #65 in FY2024 and not on the FY2025 list; up 2 since FY2022.
67 $4,175,684
Rank history: #49 in FY2021, #64 in FY2022, #71 in FY2024 and #63 in FY2025; down 3 since FY2022.
68
Heyltex Corporation
$4,142,331
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
69 $3,966,776
Rank history: not on the FY2021 list, #85 in FY2022, #56 in FY2024 and #48 in FY2025; up 16 since FY2022.
70 $3,661,004
Rank history: not on the FY2021–FY2022 lists, #86 in FY2024 and #77 in FY2025; new.
71 $3,475,375
Rank history: #72 in FY2021, #69 in FY2022, #96 in FY2024 and #72 in FY2025; down 2 since FY2022.
72 $3,435,993
Rank history: #33 in FY2021, #36 in FY2022 and not on the FY2024–FY2025 lists; down 36 since FY2022.
73 $3,188,680
Rank history: #78 in FY2021, #83 in FY2022 and not on the FY2024–FY2025 lists; up 10 since FY2022.
74 $3,110,024
Rank history: #98 in FY2021, #72 in FY2022 and not on the FY2024–FY2025 lists; down 2 since FY2022.
75 $3,087,500
Rank history: #76 in FY2021, not on the FY2022 list, not on the FY2024 list and #58 in FY2025; up 57 since FY2022.
76 $2,970,718
Rank history: #88 in FY2021, #78 in FY2022, #74 in FY2024 and not on the FY2025 list; up 2 since FY2022.
77 $2,910,508
Rank history: #81 in FY2021, not on the FY2022 list, #78 in FY2024 and not on the FY2025 list; up 24 since FY2022.
78 $2,487,692
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 290 since FY2022.
79 $2,432,346
Rank history: not on the FY2021 list, #88 in FY2022, #69 in FY2024 and not on the FY2025 list; up 9 since FY2022.
80 $2,347,701
Rank history: #92 in FY2021, #79 in FY2022, #70 in FY2024 and #65 in FY2025; down 1 since FY2022.
81 $2,175,120
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #100 in FY2025; up 128 since FY2022.
82 $2,168,515
Rank history: #48 in FY2021, #61 in FY2022, not on the FY2024 list and #87 in FY2025; down 21 since FY2022.
83 $2,133,301
Rank history: not on the FY2021–FY2022 lists, #77 in FY2024 and not on the FY2025 list; up 97 since FY2022.
84 $2,124,557
Rank history: not on the FY2021 list, #90 in FY2022 and not on the FY2024–FY2025 lists; up 6 since FY2022.
85 $2,121,117
Rank history: not on the FY2021 list, #86 in FY2022, #90 in FY2024 and #59 in FY2025; up 1 since FY2022.
86 $2,098,941
Rank history: #75 in FY2021, #81 in FY2022, #82 in FY2024 and #89 in FY2025; down 5 since FY2022.
87 $2,026,789
Rank history: not on the FY2021–FY2022 lists, #87 in FY2024 and #96 in FY2025; up 16 since FY2022.
88 $2,000,153
Rank history: #93 in FY2021, #89 in FY2022, #79 in FY2024 and #99 in FY2025; up 1 since FY2022.
89 $1,947,803
Rank history: #63 in FY2021, #99 in FY2022, not on the FY2024 list and #79 in FY2025; up 10 since FY2022.
90 $1,843,576
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #11 in FY2025; up 156 since FY2022.
91 $1,843,280
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #84 in FY2025; new.
92 $1,824,103
Rank history: #83 in FY2021, #76 in FY2022 and not on the FY2024–FY2025 lists; down 16 since FY2022.
93 $1,781,510
Rank history: not on the FY2021–FY2022 lists, #84 in FY2024 and not on the FY2025 list; up 20 since FY2022.
94 $1,759,217
Rank history: #73 in FY2021, not on the FY2022 list and not on the FY2024–FY2025 lists; returned.
95 $1,724,171
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 45 since FY2022.
96 $1,707,612
Rank history: not on the FY2021–FY2022 lists, #98 in FY2024 and #75 in FY2025; up 38 since FY2022.
97 $1,706,483
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 31 since FY2022.
98 $1,684,170
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
99 $1,647,021
Rank history: #87 in FY2021, not on the FY2022 list and not on the FY2024–FY2025 lists; up 9 since FY2022.
100 $1,585,541
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 304 since FY2022.
Show 75 more

100 of 625 contractors listed here. See the rest on GovTribe.

Rankings for the codes under NAICS 3254

Code Net obligations Largest contractor
32541 Pharmaceutical and Medicine Manufacturing $18,173,452,861 Mckesson Corporation

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $18.5 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2023 ran Oct 1, 2022 – Sep 30, 2023. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2022. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2022 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 3254 contractors in FY2023?

1. Mckesson Corporation ($10.2B), 2. Pfizer Inc. ($1.88B), 3. Amerisourcebergen Corporation ($1.38B), 4. Cencora, Inc. ($1.24B), 5. Ihealth Labs Inc. ($358M), 6. Access Bio, Inc. ($341M), 7. Abbott Laboratories ($285M), 8. Emergent Biosolutions Inc. ($242M), 9. Osang LLC ($237M), 10. Quidel Corp ($180M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work